- Short Communication
The inhibition of in vivo tumorigenesis of osteosarcoma (OS)-732 cells by antisense human osteopontin RNA
Cellular & Molecular Biology Letters volume 13, pages 11–19 (2008)
Osteopontin (OPN) is a secreted, non-collagenous, sialic acid-rich protein which functions by mediating cell-matrix interactions and cellular signaling via binding with integrins and CD44 receptors. An increasing number of studies have shown that OPN plays an important role in controlling cancer progression and metastasis. OPN was found to be expressed in many human cancer types, and in some cases, its over-expression was shown to be directly associated with poor patient prognosis. In vitro cancer cell line and animal model studies have clearly indicated that OPN can function in regulating the cell signaling that ultimately controls the oncogenic potential of various cancers. Previous studies in our laboratory demonstrated that OPN is highly expressed in human osteosarcoma (OS) cell line OS-732. In this study, we successfully reduced the tumorigenecity of OS-732 cells xenotransplanted into nude mice, using the antisense human OPN (hOPN) RNA expression vector.
Furger, K.A., Menon, R.K., Tuck, A.B., Bramwell, V.H. and Chambers, A.F. The functional and clinical roles of osteopontin in cancer and metastasis. Curr. Mol. Med. 1 (2001) 621–632.
Rittling, S.R. and Chambers, A.F. Role of osteopontin in tumour progression. Br. J. Cancer 90 (2004) 1877–1881.
Rangaswami, H., Bulbule, A. and Kundu, G.C. Osteopontin: role in cell signaling and cancer progression. Trends Cell. Biol. 16 (2006) 79–87.
Weber, G.F. The metastasis gene osteopontin: a candidate target for cancer therapy. Biochim. Biophys. Acta 1552 (2001) 61–85.
El-Tanani, M.K., Campbell, F.C., Kurisetty, V., Jin, D., McCann, M. and Rudland, P.S. The regulation and role of osteopontin in malignant transformation and cancer. Cytokine Growth Factor Rev. 17 (2006) 463–474.
Fedarko, N.S., Jain, A., Karadag, A. and Fisher, L.W. Three small integrin binding ligand N-linked glycoproteins (SIBLINGs) bind and activate specific matrix metalloproteinases. FASEB. J. 18 (2004) 734–736.
Haqq, C., Nosrati, M., Sudilovsky, D., Crothers, J., Khodabakhsh, D., Pulliam, B.L., Federman, S., Miller, J.R., Allen, R.E., Singer, M.I., Leong, S.P., Ljung, B.M., Sagebiel, R.W. and Kashani-Sabet, M. The gene expression signatures of melanoma progression. Proc. Natl. Acad. Sci. USA 102 (2005) 6092–6097.
Chakraborty, G., Jain, S., Behera, R., Ahmed, M., Sharma, P., Kumar, V. and Kundu, G.C. The multifaceted roles of osteopontin in cell signaling, tumor progression and angiogenesis. Curr. Mol. Med. 6 (2006) 819–830.
Wai, P.Y. and Kuo, P.C. The role of Osteopontin in tumor metastasis. J. Surg. Res. 121 (2004) 228–241.
Gardner, H.A., Berse, B. and Senger, D.R. Specific reduction in osteopontin synthesis by antisense RNA inhibits the tumorigenicity of transformed Rat1 fibroblasts. Oncogene 9 (1994) 2321–2326.
Denhardt, D. Osteopontin expression correlates with melanoma invasion. J. Invest. Dermatol. 124 (2005) 16–18.
Wai, P.Y., Mi, Z., Guo, H., Sarraf-Yazdi, S., Gao, C., Wei, J., Marroquin, C.E., Clary, B. and Kuo, P.C. Osteopontin silencing by small interfering RNA suppresses in vitro and in vivo CT26 murine colon adenocarcinoma metastasis. Carcinogenesis 26 (2005) 741–751.
Wu, Y., Denhardt, D.T. and Rittling, S.R. Osteopontin is required for full expression of the transformed phenotype by the ras oncogene. Br. J. Cancer 83 (2000) 156–163.
Ek, E.T., Dass, C.R. and Choong, P.F. Commonly used mouse models of osteosarcoma. Crit. Rev. Oncol. Hematol. 60 (2006) 1–8.
Greene, F.L. AJCC Cancer Staging Manual. New York: Springer-Verlag, 2002.
Liu, S.J., Hu, G.F., Liu, Y.J., Liu, S.G., Gao, H., Zhang, C.S., Wei, Y.Y., Xue, Y. and Lao, W.D. The Effect of Human Osteopontin on the Proliferation. Transmigration and Expression of Matrix Metallproteinase-2 and 9 of Osteosarcoma Cells in vitro. Chin. Med. J. (Engl.) 117 (2004) 235–240.
Liu, S.G., Wei, Y.Y., Hu, G.F., Gao, H., Liu, S.J. and Lao, W.D. An expression profile of human α-lactalbumin in the milk of transgenic mouse. Science In. Chin, Series C-Life Sciences 47 (2004) 197–202.
Porchet, N. and Aubert, J.P. Northern blot analysis of large mRNAs. Methods Mol. Biol. 125 (2000) 305–312.
Cioffi, C.L., Garay, M., Johnston, J.F., McGraw, K., Boggs, R.T., Hreniuk, D. and Monia, B.P. Selective inhibition of A-Raf and C-Raf mRNA expression by antisense oligodeoxynucleotides in rat vascular smooth muscle cells: role of A-Raf and C-Raf in serum-induced proliferation. Mol. Pharmacol. 51 (1997) 383–389.
Li, F. and Altieri, D.C. The cancer antiapoptosis mouse survivin gene: characterization of locus and transcriptional requirements of basal and cell cycle-dependent expression. Cancer Res. 59 (1999) 3143–3151.
Ru, K., Schmitt, S., James, W.I. and Wang, J.H. Growth inhibition and antimetastatic effect of antisense poly-DNP-RNA on human breast cancer cells. Oncol. Res. 11 (1999) 505–512.
Ulanova, M., Schreiber, A.D. and Befus, A.D. The future of antisense oligonucleotides in the treatment of respiratory diseases. BioDrugs 20 (2006) 1–11.
Reed, J.C., Cuddy, M., Haldar, S., Croce, C., Nowell, P., Makover, D. and Bradley, K. BCL2-mediated tumorigenicity of a human T-lymphoid cell line: synergy with MYC and inhibition by BCL2 antisense. Proc. Natl. Acad. Sci. USA 87 (1990) 3660–3664.
Zhang, X., Chen, Z., Chen, Y. and Tong, T. Delivering antisense telomerase RNA by a hybrid adenovirus/ adeno-associated virus significantly suppresses the malignant phenotype and enhances cell apoptosis of human breast cancer cells. Oncogene 22 (2003) 2405–2416.
Scotlandi, K., Avnet, S., Benini, S., Manara, M.C., Serra, M., Cerisano, V., Perdichizzi, S., Lollini, P.L., De Giovanni, C., Landuzzi, L. and Picci, P. Expression of an IGF-I receptor dominant negative mutant induces apoptosis, inhibits tumorigenesis and enhances chemosensitivity in Ewing’s sarcoma cells. Int. J. Cancer 101 (2002) 11–16.
Resnicoff, M., Sell, C., Rubini, M., Coppola, D., Ambrose, D., Baserga, R. and Rubin, R. Rat glioblastoma cells expressing an antisense RNA to the insulin-like growth factor-1 (IGF-1) receptor are nontumorigenic and induce regression of wild-type tumors. Cancer Res. 54 (1994) 2218–2222.
Oku, T., Tjuvajev, J.G., Miyagawa, T., Sasajima, T., Joshi, A., Joshi, R., Finn, R., Claffey, K.P. and Blasberg, R.G. Tumor growth modulation by sense and antisense vascular endothelial growth factor gene expression: effects on angiogenesis, vascular permeability, blood volume, blood flow, fluorodeoxyglucose uptake, and proliferation of human melanoma intracerebral xenografts. Cancer Res. 58 (1998) 4185–4192.
Belletti, B., Ferraro, P., Arra, C., Baldassarre, G., Bruni, P., Staibano, S., De Rosa, G., Salvatore, G., Fusco, A., Persico, M.G. and Viglietto, G. Modulation of in vivo growth of thyroid tumor-derived cell lines by sense and antisense vascular endothelial growth factor gene. Oncogene 18 (1999) 4860–4869.
He, Y., Zeng, Q., Drenning, S.D., Melhem, M.F., Tweardy, D.J., Huang, L. and Grandis, J.R. Inhibition of human squamous cell carcinoma growth in vivo by epidermal growth factor receptor antisense RNA transcribed from the U6 promoter. J. Natl. Cancer Inst. 90 (1998) 1080–1087.
Huber, L.C., Distler, O., Gay, R.E. and Gay, S. Antisense strategies in degenerative joint diseases: sense or nonsense? Adv. Drug Deliv. Rev. 58 (2006) 285–299.
Friedrich, I., Shir, A., Klein, S. and Levitzki, A. RNA molecules as anticancer agents. Semin. Cancer Biol. 14 (2004) 223–230.
Liu, S.J., Hu, G.F., Liu S.G. and Lao, W.D. Functional analysis of human osteopontin (hOPN) in cellular proliferation. High. Technol. Lett. 13 (2003) 25–28.
Gleave, M.E and Monia, B.P. Antisense therapy for cancer. Nat. Rev. Cancer 5 (2005) 468–479.
Folini, M. and Zaffaroni, N. Targeting telomerase by antisense-based approaches: perspectives for new anti-cancer therapies. Curr. Pharm. Des. 11 (2005) 1105–1117.
Benimetskaya, L. and Stein, C.A. Antisense therapy: recent advances and relevance to prostate cancer. Clin. Prostate Cancer 1 (2002) 20–30.
Wacheck, V. and Zangemeister-Wittke, U. Antisense molecules for targeted cancer therapy. Crit. Rev. Oncol. Hematol. 59 (2006) 65–73.
About this article
Cite this article
Liu, SJ., Zhang, DQ., Sui, XM. et al. The inhibition of in vivo tumorigenesis of osteosarcoma (OS)-732 cells by antisense human osteopontin RNA. Cell Mol Biol Lett 13, 11–19 (2008). https://doi.org/10.2478/s11658-007-0031-0
- Antisense RNA